Kimberly Yonkers to Luteal Phase
This is a "connection" page, showing publications Kimberly Yonkers has written about Luteal Phase.
Connection Strength
0.968
-
Yonkers KA, Pearlstein T, Fayyad R, Gillespie JA. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. J Affect Disord. 2005 Apr; 85(3):317-21.
Score: 0.247
-
Yonkers KA, Altemus M, Gilstad-Hayden K, Kornstein SG, Gueorguieva R. Does Symptom-Onset Treatment With Sertraline Improve Functional Impairment for Individuals With Premenstrual Dysphoric Disorder?: A Randomized Controlled Trial. J Clin Psychopharmacol. 2023 Jul-Aug 01; 43(4):320-325.
Score: 0.217
-
Yonkers KA, Kornstein SG, Gueorguieva R, Merry B, Van Steenburgh K, Altemus M. Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2015 Oct; 72(10):1037-44.
Score: 0.128
-
Steiner M, Pearlstein T, Cohen LS, Endicott J, Kornstein SG, Roberts C, Roberts DL, Yonkers K. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. J Womens Health (Larchmt). 2006 Jan-Feb; 15(1):57-69.
Score: 0.065
-
Le Bon O, Yonkers K, Armitage R. More sleep cycles in the mid-luteal phase of a healthy control. Acta Neurol Belg. 2002 Dec; 102(4):186-7.
Score: 0.053
-
Pearlstein TB, Halbreich U, Batzar ED, Brown CS, Endicott J, Frank E, Freeman EW, Harrison WM, Haskett RF, Stout AL, Yonkers KA. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry. 2000 Feb; 61(2):101-9.
Score: 0.043
-
Gurguis GN, Yonkers KA, Phan SP, Blakeley JE, Williams A, Rush AJ. Adrenergic receptors in premenstrual dysphoric disorder: I. Platelet alpha 2 receptors: Gi protein coupling, phase of menstrual cycle, and prediction of luteal phase symptom severity. Biol Psychiatry. 1998 Oct 01; 44(7):600-9.
Score: 0.039
-
Yonkers KA, Halbreich U, Freeman E, Brown C, Endicott J, Frank E, Parry B, Pearlstein T, Severino S, Stout A, Stone A, Harrison W. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA. 1997 Sep 24; 278(12):983-8.
Score: 0.037
-
Yonkers KA. Antidepressants in the treatment of premenstrual dysphoric disorder. J Clin Psychiatry. 1997; 58 Suppl 14:4-10; discussion 11-3.
Score: 0.035
-
Armitage R, Yonkers KA. Case report: menstrual-related very short REM latency in a healthy normal control. Sleep. 1994 Jun; 17(4):345-7.
Score: 0.029
-
Severino SK, Yonkers KA. A literature review of psychotic symptoms associated with the premenstruum. Psychosomatics. 1993 Jul-Aug; 34(4):299-306.
Score: 0.027
-
Pearlstein T, Yonkers KA, Fayyad R, Gillespie JA. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. J Affect Disord. 2005 Apr; 85(3):275-82.
Score: 0.015
-
Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol. 2002 Dec; 100(6):1219-29.
Score: 0.013
-
Gurguis GN, Yonkers KA, Blakeley JE, Phan SP, Williams A, Rush AJ. Adrenergic receptors in premenstrual dysphoric disorder. II. Neutrophil beta2-adrenergic receptors: Gs protein coupling, phase of menstrual cycle and prediction of luteal phase symptom severity. Psychiatry Res. 1998 Jun 02; 79(1):31-42.
Score: 0.010
-
Halbreich U, Petty F, Yonkers K, Kramer GL, Rush AJ, Bibi KW. Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. Am J Psychiatry. 1996 May; 153(5):718-20.
Score: 0.008